Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01784523 · ClinicalTrials.gov registry record · Phase 3
Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
A Phase 3 study, sponsored by Hospital for Special Surgery, New York.
- Terminated
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT01784523: Clinical Trial Phase 3 study, sponsored by Hospital for Special Surgery, New York.
NCT01784523 is a Phase 3 study that was terminated before completion, run by Hospital for Special Surgery, New York. The registered enrollment target is 11 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01784523, a Phase 3 study, was terminated before completion, sponsored by Hospital for Special Surgery, New York.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
In this multi-center international study, our aim is to determine the effectiveness of HCQ for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases.
Primary Outcome
To determine the efficacy of Hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis free patients with no other systemic autoimmune diseases over the five year study period.
Interventions
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-09-30 |
| Phase | Phase 3 |
Why NCT01784523 stopped before completion
NCT01784523 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Hydroxychloroquine is the first listed.
NCT01784523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01784523 about?
NCT01784523 is a clinical study titled "Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients". In this multi-center international study, our aim is to determine the effectiveness of HCQ for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases.
What is the current status of trial NCT01784523?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2013-02. Estimated completion is 2015-09-30.
What interventions are being tested in trial NCT01784523?
The interventions under investigation include: Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT01784523?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01784523's enrollment target sits among peer trials
11 1989th of 2000 higher than 12 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia